Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $974,446.20 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president owned 21,266 shares of the company’s stock, valued at $1,827,387.38. This represents a 34.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Stock Down 0.1%

Shares of NYSE EW opened at $85.23 on Thursday. The business has a 50-day moving average of $82.71 and a two-hundred day moving average of $81.41. The company has a market capitalization of $49.50 billion, a price-to-earnings ratio of 46.57, a price-to-earnings-growth ratio of 2.22 and a beta of 0.93. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the business. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences during the fourth quarter worth $27,000. True Wealth Design LLC increased its position in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $28,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Wells Fargo & Company lifted their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Truist Financial set a $89.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, February 11th. UBS Group reissued a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Finally, Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.